Your browser is no longer supported. Please, upgrade your browser.
Settings
JAZZ Jazz Pharmaceuticals Public Limited Company daily Stock Chart
JAZZ [NASD]
Jazz Pharmaceuticals Public Limited Company
Index- P/E61.77 EPS (ttm)2.67 Insider Own2.90% Shs Outstand61.34M Perf Week2.68%
Market Cap10.12B Forward P/E14.07 EPS next Y11.72 Insider Trans-11.55% Shs Float59.64M Perf Month-14.44%
Income178.10M PEG3.22 EPS next Q2.56 Inst Own95.70% Short Float4.01% Perf Quarter-9.27%
Sales1.28B P/S7.92 EPS this Y-73.50% Inst Trans6.81% Short Ratio5.48 Perf Half Y-4.52%
Book/sh23.64 P/B6.98 EPS next Y21.33% ROA8.00% Target Price205.25 Perf Year1.15%
Cash/sh15.02 P/C10.98 EPS next 5Y19.21% ROE19.50% 52W Range137.34 - 194.73 Perf YTD0.73%
Dividend- P/FCF22.47 EPS past 5Y43.30% ROI3.70% 52W High-15.30% Beta0.57
Dividend %- Quick Ratio5.40 Sales past 5Y55.60% Gross Margin91.70% 52W Low20.09% ATR7.24
Employees870 Current Ratio5.50 Sales Q/Q14.60% Oper. Margin38.40% RSI (14)37.31 Volatility3.56% 4.37%
OptionableYes Debt/Eq0.94 EPS Q/Q100.00% Profit Margin20.80% Rel Volume0.79 Prev Close168.82
ShortableYes LT Debt/Eq0.92 EarningsAug 05 AMC Payout0.00% Avg Volume437.04K Price164.93
Recom1.80 SMA20-7.75% SMA50-8.71% SMA200-6.30% Volume342,304 Change-2.30%
Jun-29-15Reiterated UBS Buy $190 → $210
May-26-15Reiterated Guggenheim Buy $210 → $220
Feb-25-15Reiterated Deutsche Bank Buy $176 → $185
Feb-20-15Initiated BMO Capital Markets Outperform $200
Nov-05-14Upgrade R. F. Lafferty Neutral → Buy $200
May-09-14Reiterated R. F. Lafferty Neutral $140 → $130
Apr-17-14Initiated Canaccord Genuity Buy $163
Mar-07-14Resumed Barclays Overweight $200
Feb-26-14Reiterated Stifel Buy $145 → $195
Jan-14-14Reiterated UBS Buy $130 → $164
Jan-14-14Downgrade R. F. Lafferty Buy → Neutral $140
Dec-06-13Reiterated UBS Buy $110 → $130
Nov-25-13Reiterated FBR Capital Outperform $105 → $198
Nov-25-13Reiterated Barclays Overweight $112 → $130
Nov-13-13Reiterated R. F. Lafferty Buy $102 → $118
Oct-30-13Initiated FBR Capital Outperform $105
Sep-13-13Reiterated UBS Buy $87 → $98
Aug-22-13Initiated R. F. Lafferty Buy $102
Aug-07-13Reiterated UBS Buy $80 → $87
Aug-07-13Reiterated Cantor Fitzgerald Buy $86 → $97
Aug-25-15 09:30AM  Alcobra, Jazz Pharmaceuticals, Nippon Telecom and Toyota Motor highlighted as Zacks Bull and Bear of the Day
09:01AM  Bear of the Day: Jazz Pharma (JAZZ)
Aug-21-15 01:15PM  Why Medivation is a Stunning Biotech Opportunity -6.26%
Aug-19-15 08:53AM  Jazz Pharmaceuticals Plc Earnings Analysis: By the Numbers Q2*, 2015
Aug-13-15 01:04PM  JAZZ PHARMACEUTICALS PLC Financials
Aug-11-15 08:33AM  This Undervalued Biotech Company Just Filed For FDA Approval and No One Noticed
Aug-10-15 09:22AM  A Victory For Free Speech And Common Sense at Forbes
Aug-06-15 03:12PM  Jazz Pharmaceuticals Misses on Q2 Earnings, Affirms View - Analyst Blog
04:27AM  Edited Transcript of JAZZ earnings conference call or presentation 5-Aug-15 8:30pm GMT
Aug-05-15 06:22PM  Jazz Pharma Q2 Earnings Meet Views, Revenue Light at Investor's Business Daily
06:06PM  Jazz Pharmaceuticals Beats on Earnings, Misses on Revenues - Stocks in the News
05:39PM  Jazz meets 2Q profit forecasts
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today
04:13PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Jazz Pharmaceuticals Announces Second Quarter 2015 Financial Results PR Newswire
03:27PM  Tesla, Fitbit Top 4 Key Earnings Late Wed. at Investor's Business Daily
07:07AM  Q2 2015 Jazz Pharmaceuticals PLC Earnings Release - After Market Close
Aug-03-15 06:21PM  More Pharma Buyouts Ahead? 3 Top Stocks In Buy Range at Investor's Business Daily
02:18PM  Health, Consumer ETFs Holding IBD 50 Stocks Set To Report at Investor's Business Daily
01:05PM  5 Top Medical Stocks Reporting Earnings This Week at Investor's Business Daily
11:06AM  Pharma Stocks Show a Positive Trend
Aug-01-15 08:02AM  IBD 50: 10 Top Stocks Reporting Earnings This Week at Investor's Business Daily
Jul-31-15 10:56AM  Jazz Pharma Could Be Worth Over $200 If Xyrem Adds Long-Term Value: Here's How
Jul-30-15 06:23PM  Six International Leaders Preparing To Report Results at Investor's Business Daily
12:32PM  Will Q2 Earnings Wake Up Jazz Pharma's Stock? at Investor's Business Daily
11:19AM  Will Jazz Pharma's Stock Awake With Q2 Earnings?
Jul-29-15 01:02PM  This Winning Biotech Stock Looks Like a Buy at Motley Fool
09:00AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events
Jul-28-15 04:03PM  Wakefulness Drug Xyrem Keeps Jazz Pharmaceuticals Up at Investor's Business Daily
Jul-22-15 04:05PM  Jazz Pharmaceuticals to Report 2015 Second Quarter Financial Results on August 5, 2015 PR Newswire
Jul-09-15 08:56AM  Barclays Expects M&A In Specialty Pharma To Continue, Likes Valeant And Jazz
Jul-08-15 02:04PM  Rate Hikes Won't Kill Pharma M&A Boomand These Stocks Could Be Next at Barrons.com
Jul-06-15 03:05PM  Are Patent Challenges Paying Off For Kyle Bass?
Jul-01-15 04:05PM  Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 PR Newswire
Jun-29-15 03:53PM  Why Jazz Pharmaceuticals Is Winning
11:11AM  Jazz Pharma Still Loved At UBS, Firm Hikes Price Target To $210
Jun-19-15 03:34PM  Jazz Financing I Ltd. -- Moody's assigns Ba2 to Jazz's new senior secured bank facilities; stable outlook at Moody's
Jun-18-15 04:03PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material De
Jun-15-15 01:47PM  Should Active Managers Blame the Benchmark? at Barrons.com
Jun-11-15 11:37AM  Edited Transcript of JAZZ presentation 10-Jun-15 5:40pm GMT
Jun-09-15 09:40AM  Jazz Pharmaceuticals' Sleep Disorder Drug Enters Phase III - Analyst Blog
08:00AM  Aytu BioScience Acquires Commercial-Stage Prostate Cancer Biologic PR Newswire
Jun-04-15 09:05AM  Jazz Pharmaceuticals to Present Abstracts from Ongoing Evaluations of Xyrem® (sodium oxybate) at SLEEP 2015 PR Newswire
May-29-15 11:20AM  Who's The Next Big Pharma Acquisition?
May-15-15 04:05PM  Jazz Pharmaceuticals Announces Participation in Two Investor Conferences PR Newswire
May-08-15 03:08PM  Jazz Pharmaceuticals Misses on Q1 Earnings, Affirms View - Analyst Blog
07:02AM  Jazz Pharmaceuticals (JAZZ) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
May-07-15 07:52PM  Jazz misses Street 1Q forecasts
06:43PM  Medivation, Jazz Q1 Reports Miss; Regeneron Beats at Investor's Business Daily
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today
04:15PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Jazz Pharmaceuticals Announces First Quarter 2015 Financial Results PR Newswire
04:05PM  Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update Business Wire
03:22PM  High Expectations For Jazz Pharmaceuticals
07:07AM  Q1 2015 Jazz Pharmaceuticals PLC Earnings Release - After Market Close
May-06-15 09:32PM  Under pressure, FDA to hold public meeting on off-label use Reuters
May-01-15 05:06PM  Handles Give Lower Buy Points, But Watch Out For Faulty Ones Investor's Business Daily
Apr-23-15 04:24PM  Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 at noodls
04:05PM  Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 PR Newswire
Apr-18-15 10:41AM  Why This Trader Is Worried About Jazz Pharmaceuticals
Apr-14-15 01:45PM  Hillary Clinton is bashing CEOs -- while taking their money
Apr-13-15 05:17PM  Autohome, Other Foreign Stock Leaders Seen Posting Big Q1 at Investor's Business Daily
Apr-08-15 04:40PM  How Much Further Can Jazz Pharmaceuticals Fall? +6.89%
12:07AM  [$$] New Hedge Fund Strategy: Dispute the Patent, Short the Stock at The Wall Street Journal
Apr-07-15 07:24PM  Kyle Bass's New Tack: Dispute the Patent, Short the Stock at The Wall Street Journal
Apr-01-15 12:01PM  How to make it rain in April
Mar-30-15 08:14AM  Italys Sigma-Tau Rare Diseases Unit Said to Attract Interest at Bloomberg
Mar-23-15 09:11AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements
Mar-18-15 08:10AM  Oppenheimer: Bullish Technical Analysis Of 5 Healthcare Names
08:02AM  This Drugmaker Stock Is Attempting A Re-Breakout at Investor's Business Daily
Mar-04-15 04:20PM  Jazz Pharmaceuticals Up on U.S. Approval of Xyrem REMS - Analyst Blog
Mar-03-15 06:14AM  Nasdaq 5000 built on biotech this time
Mar-02-15 01:18PM  4 Big-Volume Stocks to Trade for Breakouts: La Jolla Pharma and More at TheStreet
08:16AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events
Feb-26-15 04:54PM  Splunk Shoots Up After Hours; Monster Beverage Also Up at Investor's Business Daily
11:51AM  Jazz Pharmaceuticals Tops Q4 Earnings And Tests Buy Point at Investor's Business Daily
10:10AM  Company News for February 26, 2015 - Corporate Summary
Feb-25-15 03:34PM  Heavy News Day For Several Biotech Stocks
12:28PM  8 Stories JP Morgan Is Watching Today Benzinga
10:23AM  Jazz Pharmaceuticals (JAZZ) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
09:30AM  Jazz Pharmaceuticals Tops Q4 Earnings, Provides Guidance - Analyst Blog Zacks
Feb-24-15 08:37PM  Jazz Pharmaceuticals Sinks On Outlook, Halt In Drug Trial Benzinga
07:09PM  Jazz tops Street 4Q forecasts AP
06:17PM  Jazz Pharma Tops, But Stock Falls On Guidance Investor's Business Daily
04:50PM  Hewlett-Packard, Jazz Pharmaceuticals Fall After-Hours at Investor's Business Daily
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today CCBN
04:25PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Pr EDGAR Online
11:56AM  Stocks Rise A Bit On Yellen Testimony, Home Depot Results at Investor's Business Daily
07:07AM  Q4 2014 Jazz Pharmaceuticals PLC Earnings Release - After Market Close CCBN
Feb-23-15 05:55PM  Avago, Jazz, MercadoLibre Build Bases Before Q4 Reports at Investor's Business Daily
04:05PM  Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March PR Newswire
Feb-20-15 02:37PM  Street Talk: ABBV, ARII, DSW, MRVL & JAZZ CNBC
12:52PM  Coverage initiated on Jazz Pharma by BMO Capital Markets Briefing.com
Feb-18-15 06:07AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Feb-14-15 08:02AM  Actavis Leads IBD 50 Stocks With Earnings This Week at Investor's Business Daily
Feb-13-15 05:07PM  S&P 500 Closes At Record High As Oil Stocks Rebound at Investor's Business Daily
Feb-12-15 08:30AM  Jazz Pharmaceuticals to Present Data on Defibrotide, an Investigational Treatment, in Patients with Hepatic Veno-Occlusive Disease (VOD) at BMT Tandem Meetings PR Newswire
Feb-10-15 04:05PM  Jazz Pharmaceuticals to Report 2014 Fourth Quarter and Full Year Financial Results on February 24, 2015 PR Newswire
Feb-04-15 07:30AM  Lightlake Partner De-Risks Drug Platform; Implies Shares Trade at 1/4 Fair Value Company Spotlight
Jan-22-15 06:36PM  Top World Stocks Close In On Buy Points, New Highs at Investor's Business Daily
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate that is in phase I clinical trail for use in patients with narcolepsy. In addition, it develops products in the areas of hematology and oncology, such as JZP-416, which has completed phase I clinical trial for the treatment of patients with ALL who are hypersensitive to E. coli-derived asparaginase; and Leukotac, an anti-CD25 monoclonal antibody that is in phase III clinical trials for the treatment of steroid-refractory acute graft vs. host disease. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ENRIGHT PATRICK GDirectorAug 27Sale167.8742571,3451,734Aug 31 04:06 PM
COZADD BRUCE CChairman and CEOAug 11Sale177.822,500444,550296,855Aug 12 05:35 PM
Hooper Suzanne SawochkaEVP and General CounselAug 11Sale177.824,000711,28037,855Aug 12 05:33 PM
Cox Russell J.EVP & Chief Commercial OfficerAug 11Sale177.8250088,91058,602Aug 12 05:31 PM
Treacy PaulSVP, Technical OperationsAug 11Sale177.821,330236,49411,401Aug 11 05:54 PM
Sohn Catherine A.DirectorAug 11Sale177.82654116,2935,384Aug 11 05:44 PM
Sohn Catherine A.DirectorAug 10Sale180.00801144,1806,038Aug 11 05:44 PM
RIEDEL NORBERT GDirectorAug 10Sale180.00801144,1784,865Aug 11 05:41 PM
Winningham Rick EDirectorAug 10Sale180.00801144,17814,659Aug 11 05:46 PM
McSharry Heather AnnDirectorAug 10Sale179.99867156,0526,093Aug 11 05:37 PM
Gray PeterDirectorAug 10Sale180.00867156,0595,389Aug 11 05:35 PM
ENRIGHT PATRICK GDirectorAug 10Sale182.0210,0001,820,1775,500Aug 11 05:34 PM
ENRIGHT PATRICK GDirectorAug 10Sale180.00801144,1782,159Aug 11 05:34 PM
BERNS PAUL LDirectorAug 10Sale180.00801144,1785,589Aug 11 05:32 PM
Hooper Suzanne SawochkaEVP & General CounselJul 14Option Exercise46.834,000187,32050,420Jul 16 05:47 PM
Hooper Suzanne SawochkaEVP & General CounselJul 14Sale177.794,000711,16046,420Jul 16 05:47 PM
COZADD BRUCE CChairman & CEOJul 14Sale177.795,000888,950542,224Jul 16 05:47 PM
ENRIGHT PATRICK GDirectorJul 06Sale177.1110,0001,771,0555,696Jul 08 04:03 PM
Hooper Suzanne SawochkaEVP & General CounselJun 09Option Exercise46.834,000187,32050,420Jun 11 05:37 PM
Hooper Suzanne SawochkaEVP & General CounselJun 09Sale173.164,000692,64046,420Jun 11 05:37 PM
WILSON KAREN JSVP, Finance & PAOJun 02Sale180.0025746,26025,642Jun 03 06:34 PM
WILSON KAREN JSVP, Finance & PAOJun 01Option Exercise50.195,494275,73429,893Jun 03 06:34 PM
ENRIGHT PATRICK GDirectorJun 01Sale178.7310,0001,787,3365,893Jun 03 04:04 PM
WILSON KAREN JSVP, Finance & PAOJun 01Sale179.575,494986,54825,899Jun 03 06:34 PM
McGill IainSVP, Europe and Rest of WorldMay 26Option Exercise49.357,334361,90132,030May 28 07:11 PM
McGill IainSVP, Europe and Rest of WorldMay 26Sale179.487,3341,316,32624,696May 28 07:11 PM
O'Keefe Kenneth WDirectorMay 12Option Exercise46.834,500210,73510,650May 14 08:19 PM
Hooper Suzanne SawochkaEVP & General CounselMay 12Option Exercise46.832,07397,07950,297May 14 08:30 PM
RIEDEL NORBERT GDirectorMay 12Sale173.86650113,0104,356May 14 08:12 PM
Gray PeterDirectorMay 12Sale173.86704122,4004,946May 14 07:58 PM
Hooper Suzanne SawochkaEVP & General CounselMay 12Sale173.854,000695,40046,297May 14 08:30 PM
COZADD BRUCE CChairman & CEOMay 12Sale173.855,000869,250551,967May 14 08:25 PM
O'Keefe Kenneth WDirectorMay 12Sale174.901,218213,0269,432May 14 08:19 PM
ENRIGHT PATRICK GDirectorMay 11Sale176.1810,0001,761,7966,089May 13 04:01 PM
Cox Russell J.EVP & COOApr 14Sale181.4550090,72564,553Apr 16 08:10 PM
Hooper Suzanne SawochkaEVP & General CounselApr 14Sale181.454,000725,80048,224Apr 16 08:04 PM
COZADD BRUCE CChairman & CEOApr 14Sale181.455,000907,250556,967Apr 16 07:40 PM
ENRIGHT PATRICK GDirectorApr 06Sale169.1410,0001,691,4196,286Apr 08 04:05 PM
Mulligan SeamusDirectorMar 25Sale174.5950,0008,729,5221,157,205Mar 27 06:20 PM
Mulligan SeamusDirectorMar 18Sale185.0050,0009,250,0001,207,205Mar 20 08:22 PM
Hooper Suzanne SawochkaEVP & General CounselMar 10Option Exercise46.831,85186,68254,075Mar 12 08:27 PM
COZADD BRUCE CChairman & CEOMar 10Sale170.355,000851,750561,967Mar 12 08:16 PM
Hooper Suzanne SawochkaEVP & General CounselMar 10Sale170.361,851315,33652,224Mar 12 08:27 PM
Cox Russell J.EVP & COOMar 05Sale175.1050087,55065,053Mar 09 08:38 PM
WILSON KAREN JSVP, Finance & PAOMar 04Option Exercise28.035,159144,61026,205Mar 05 06:51 PM
WILSON KAREN JSVP, Finance & PAOMar 03Sale176.272,598457,94921,046Mar 05 06:51 PM
ENRIGHT PATRICK GDirectorMar 02Sale176.0010,0001,760,0316,482Mar 04 04:05 PM
Hooper Suzanne SawochkaEVP & General CounselFeb 10Option Exercise46.831,85186,68249,426Feb 12 07:26 PM
Tobias Jeffrey KEVP, R&D & CMOFeb 10Option Exercise46.835,000234,15040,063Feb 12 07:38 PM
Tobias Jeffrey KEVP, R&D & CMOFeb 10Sale166.825,000834,11835,063Feb 12 07:38 PM
ENRIGHT PATRICK GDirectorFeb 10Sale166.8510,0001,668,5186,679Feb 12 04:03 PM
Hooper Suzanne SawochkaEVP & General CounselFeb 10Sale166.901,851308,93247,575Feb 12 07:26 PM
COZADD BRUCE CChairman & CEOFeb 10Sale166.905,000834,500549,131Feb 12 07:19 PM
Hooper Suzanne SawochkaEVP and General CounselJan 13Option Exercise46.831,85186,68249,426Jan 15 07:43 PM
COZADD BRUCE CChairman and CEOJan 13Sale161.735,000808,650554,131Jan 15 07:40 PM
Hooper Suzanne SawochkaEVP and General CounselJan 13Sale161.731,851299,36247,575Jan 15 07:43 PM
ENRIGHT PATRICK GDirectorJan 05Sale160.2510,0001,602,4836,875Jan 07 04:02 PM
Mulligan SeamusDirectorDec 26Sale166.193,308549,7611,257,205Dec 29 07:03 AM
Mulligan SeamusDirectorDec 24Sale165.6313,4172,222,2341,260,513Dec 29 07:03 AM
Mulligan SeamusDirectorDec 23Sale162.2233,2755,397,8961,273,930Dec 29 07:03 AM
ENRIGHT PATRICK GDirectorDec 12Sale170.982,343400,6031,650Dec 16 04:04 PM
Hooper Suzanne SawochkaEVP and General CounselDec 09Option Exercise46.831,34763,08049,647Dec 11 06:25 PM
COZADD BRUCE CChairman and CEODec 09Sale178.795,000893,950559,131Dec 11 06:09 PM
Hooper Suzanne SawochkaEVP and General CounselDec 09Sale178.791,852331,11947,795Dec 11 06:25 PM
Tobias Jeffrey KEVP, Research & Dev and CMONov 24Sale170.124,598782,23134,940Nov 25 06:51 PM
Tobias Jeffrey KEVP, Research & Dev and CMONov 14Sale173.321,000173,32039,538Nov 18 05:40 PM
Hooper Suzanne SawochkaEVP and General CounselNov 11Option Exercise46.8366731,23650,101Nov 13 06:55 PM
Hooper Suzanne SawochkaEVP and General CounselNov 11Sale173.631,852321,56348,249Nov 13 06:55 PM
COZADD BRUCE CChairman and CEONov 11Sale173.635,000868,150564,023Nov 13 06:45 PM
ENRIGHT PATRICK GDirectorNov 10Sale171.0910,0001,710,8587,268Nov 12 04:04 PM
McGill IainHead of EUSA Int'l & SVPNov 07Option Exercise50.095,666283,78930,490Nov 10 06:25 PM
McGill IainHead of EUSA Int'l & SVPNov 07Sale172.037,0661,215,53023,424Nov 10 06:25 PM
WILSON KAREN JSVP, Finance & PAONov 06Option Exercise50.347,000352,41028,713Nov 10 05:48 PM
WILSON KAREN JSVP, Finance & PAONov 06Sale170.117,5961,292,15721,117Nov 10 05:48 PM
COZADD BRUCE CChairman and CEOOct 14Sale142.775,000713,850569,023Oct 16 07:06 PM
Tobias Jeffrey KEVP, Research & Dev and CMOOct 10Sale154.041,000154,04040,538Oct 14 06:35 PM
ENRIGHT PATRICK GDirectorOct 06Sale160.5610,0001,605,6337,465Oct 08 06:01 AM
Mulligan SeamusDirectorSep 25Sale161.8414,7062,380,0641,307,205Sep 26 06:45 PM
Mulligan SeamusDirectorSep 24Sale163.7035,2945,777,6921,321,911Sep 26 06:45 PM
Tobias Jeffrey KEVP, Research & Dev and CMOSep 12Sale171.221,000171,22041,538Sep 15 07:10 PM
WILSON KAREN JSVP, Finance & PAOSep 11Option Exercise27.463,00082,38024,713Sep 15 06:53 PM
Mulligan SeamusDirectorSep 11Sale175.0050,0008,750,0001,357,205Sep 15 06:56 PM
WILSON KAREN JSVP, Finance & PAOSep 11Sale175.003,000525,00021,713Sep 15 06:53 PM
COZADD BRUCE CChairman and CEOSep 09Sale170.325,000851,600574,023Sep 10 09:07 PM
Hooper Suzanne SawochkaEVP and General CounselSep 08Option Exercise46.8366731,23652,471Sep 10 09:05 PM
WILSON KAREN JSVP, Finance & PAOSep 08Option Exercise27.462,50068,65024,213Sep 10 09:06 PM
WILSON KAREN JSVP, Finance & PAOSep 08Sale170.002,500425,00021,713Sep 10 09:06 PM
Hooper Suzanne SawochkaEVP and General CounselSep 08Sale168.001,852311,13650,619Sep 10 09:05 PM